ArticleAmerican journal of cardiovascular disease2026
Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.
Article in American journal of cardiovascular disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac amyloidosis is underdiagnosed. Amyloid deposits cause progressive diastolic dysfunction of a nondilated ventricle. Among the main subtypes, transthyretin amyloidosis (ATTR) affects 1 in 2,000 people, while light-chain (AL) amyloidosis is increasing in prevalence. Early identification of risk factors and prompt intervention may prevent severe complications. This study aimed to identify the risk factors for developing cardiac amyloidosis and its associated morbidity and mortality.
methodsThis retrospective cohort study used the National Inpatient Sample (2016-2020) to examine patients hospitalized with cardiac amyloidosis identified by ICD-10 codes. Over 50 risk factors, including hematologic, rheumatologic, and renal conditions, were evaluated as possible contributors. Predictors of cardiac amyloidosis and mortality were analyzed by demographic group. Inclusion required a primary or secondary diagnosis. Multiple logistic regression, adjusted for age, sex, and comorbidities, assessed associations. The primary outcome was cardiac amyloidosis; the secondary outcome was in-hospital mortality.
resultsThere were 23,119 patients with cardiac amyloidosis. The mean age was 72.23 years, and 58% were male. Hereditary transthyretin amyloidosis (OR 215.89, 95% CI: 176.17-264.56) and familial Mediterranean fever (OR 111.99, 95% CI: 72.39-173.24) showed the strongest associations, both statistically significant (P<0.001). Additional risk factors included hematologic conditions, such as multiple myeloma (OR 15.31), Waldenström's macroglobulinemia (OR 6.99), and MGUS (OR 4.45), all P<0.001. Renal conditions such as chronic kidney disease (OR 1.83), end-stage renal disease (OR 2.76), and renal transplant (OR 2.4), and rheumatologic conditions such as Sjögren's syndrome (OR 2.04) and sarcoidosis (OR 1.69) were also significant (all P<0.001). By demographics, Black race (OR 2.52, P<0.001), Asian race (OR 1.11, P = 0.034), and older age (OR 1.05, P<0.001) were associated with increased risk. Notably, asthma, diabetes, and obesity were not linked to cardiac amyloidosis. In-hospital mortality increased with ESRD (OR 2.4), multiple myeloma (OR 1.41), and older age (OR 1.015).
conclusionHereditary transthyretin amyloidosis, familial Mediterranean fever, and Black race were the strongest risk factors, while end-stage renal disease and multiple myeloma correlated with higher in-hospital mortality. ICD-10-based diagnoses may limit accuracy. This stresses the need for improved risk stratification and targeted screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.